Back
ImmunityBio, Inc. 10K Form
Sell
30
IBRX
ImmunityBio, Inc.
Last Price:
$2.37
Seasonality Move:
74.15%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive IBRX News And Ratings
See the #1 stock for the next 7 days that we like better than IBRX
IBRX Financial Statistics
Sales & Book Value
| Annual Sales: | $14.7M |
|---|---|
| Cash Flow: | $-69.7M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-0.53 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -0.42050 |
|---|---|
| Net Income (TTM): | $-348.7M |
| Gross Margin: | $-2.8M |
| Return on Equity: | 0% |
| Return on Assets: | -88.4% |
ImmunityBio, Inc. Earnings Forecast
Key ImmunityBio, Inc. Financial Ratios
-
The Gross Profit Margin over the past 4 years for IBRX is -19.05%.
-
The Selling, General & Administrative Expenses for IBRX have been equal to 1,144.68% of Gross Profit Margin.
-
The Research & Development expenses have been 1,275.99% of Revenue.
-
The Net Earning history of IBRX is -2,805.32% of Total Revenues.
-
Per Share Earnings over the last 6 years have been positive in 1 years.
ImmunityBio, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | IBRX |
| Website: | immunitybio.com |
Debt
| Debt-to-Equity Ratio: | -1.64 |
|---|---|
| Current Ratio: | 5.77 |
| Quick Ratio: | 5.07 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
IBRX Technical Analysis vs Fundamental Analysis
Sell
30
ImmunityBio, Inc. (IBRX)
is a Sell
Is ImmunityBio, Inc. a Buy or a Sell?
-
ImmunityBio, Inc. stock is rated a SellThe current ImmunityBio, Inc. [IBRX] share price is $2.29. The Score for IBRX is 30, which is 40% below its historic median score of 50, and infers higher risk than normal.